Indian Bio-Pharmaceuticals Industry poised for growth : INR 2891.70 Billion Between 2018-2023


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Indian Bio-Pharmaceuticals Industry
India’s bio-pharmaceuticals market is anticipated to succeed in the worth of INR 2,891.70 Bn in FY 2023, amplifying at a compound annual rate of growth (CAGR) of ~31.7% since FY 2018.

India presently serves to nearly 50% of the world's demand for pharmaceutical products, princely part of which are based on the usage of biotechnological applications. Currently, biopharmaceuticals are one among the fastest-growing biotechnology segments in India. The significant biopharmaceutical clusters of India are located in Haridwar, Sikkim, Hyderabad, Vishakhapatnam, Chennai, Pondicherry, Mysore, Mumbai, Ahmedabad, and Delhi NCR.


Government initiatives and investments:
The major investors within the Indian bio-pharmaceutical market are AstraZeneca, Johnson & Johnson, GlaxoSmithKline (GSK), Nipro and Otsuka. In 2017, 46 mergers and acquisition (M&A) deals were signed within the Indian biopharmaceutical market, generating business worth INR 94.77 Bn. The Indian government has taken the initiative to line up an electronic platform for regulating online pharmacies. Pharma Vision 2020' has been unveiled in order that India can emerge as a worldwide leader in terms of end-to-end drug manufacturing.


Key growth drivers of the market:
India comprises of ~0.13 Mn highly skilled and experienced scientists who function a robust network for the business process of the biopharmaceutical industry. With the assistance of the tutorial qualifications and skillset of those people, India is taken into account to be a big centre for biopharmaceutical research and development (R&D), especially for vaccine manufacturing. The Government of India has approved an investment of INR 15,000 Mn under the Innovate in India (i3) program, for collaboration of commercial organizations and academic organizations over subsequent five years. This program is taken into account to act as a big action of the govt in its way of boosting bio-pharmaceutical production within the country.


Key deterrents to the growth of the market:
It often takes an extended time for the manufacturing companies to launch a replacement market-ready bio-pharmaceutical product in India thanks to the existence of various regulatory challenges within the process.
Also, the Indian biopharmaceutical industry lacks proper infrastructure regarding limited government-sponsored laboratory space, consumables, chemical components, and equipment, which acts as a big hindrance to the expansion of the market.

Tags : #indian #biopharma #growth #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026